The Measurement Problem Behind Two Decades of Neurology Trial Failures
The FDA now treats continuous, real-time data sharing as a regulatory direction of travel rather than a theoretical future. The neurology field should pay close attention.
French Startup Gains FDA Clearance for First In‑Ear EEG Device
French startup Naox Technologies this month became the first company to receive FDA 510(k) clearance for an in-ear EEG device. The system seeks to improve care for neurological conditions like epilepsy, Alzheimer’s and sleep disorders by capturing brain activity in everyday settings that traditional scalp-based EEGs often miss.
presented by
Closing the Quality-Affordability Gap in Workplace Mental Health
In an interview, Kyan Health Co-Founder and Chief Commercial Officer Konstantin Struck discussed how Kyan gives mid-market and enterprise employers access to premium workforce mental healthcare, at a price point that is affordable.
Breakthrough Therapies Aren’t Enough: What Neurology Needs Now
With new therapies being approved, and many others in the pipeline, they raise a critical question: Is our healthcare system prepared to deliver them effectively and sustainably?
presented by
The 3 Best Options to Buy Telemedicine Carts for Neurology Care
Neurologists and health care practitioners must evolve with the world. Telemedicine carts assist in this evolution by serving as an intermediary between patients and doctors.
Merck KGaA Expands in AI-Driven R&D With Two Drug Discovery Deals
Specific targets were not disclosed, but Merck KGaA is betting the artificial intelligence technologies of Exscientia and BenevolentAI will discover new drugs for cancer, neurology, and immunology.
Rapport Therapeutics Snags $150M to Develop Precision Neurology Meds
Rapport Therapeutics, a clinical-stage biotech that was founded last year, raised $150 million in Series B financing, bringing its total funding to date to $250 million. The company's platform leverages receptor-associated proteins to create neurology drugs that have more focused activity in the brain, going after disease-driving circuits and cell types.
presented by
Top 7 Modern AI-Powered EAP Providers for Global Workforces in 2026
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
GrayMatters Health Earns FDA Clearance for PTSD Neuromodulation Device
GrayMatters Health recently received 510(k) clearance from the FDA to market its flagship product, which is a self-neuromodulation digital therapy for PTSD. The device uses neurofeedback on specific biomarkers to help patients identify and utilize their own mental strategy for lowering their emotional response.
California dreamin’: A VC firm’s vision for West Coast-focused biotech investment
Red Tree Venture Capital has closed a $272 million fund focused on investing in West Coast life sciences companies. The firm’s founders say they’re filling a need by providing financial support for innovations emerging from the region’s academic labs.
Memory Health CEO shares approach to combating Alzheimer’s disease
Memory Health CEO Edward Shehab talked about taking a preventive approach to neurodegenerative conditions.
MindMaze fuels growth in gamified neurorehab with $105M in financing
The financing round was led by Concord Health Partners, with AlbaCore Capital Group and Hambro Perks also contributing. The latest haul follows a $125 million raise that the company announced in October.
presented by
Inside an Automated Healthcare Practice: Redesigning Care Around People, Not Paperwork
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
AI that flags urgent cases for radiologists gets FDA clearance
Nines received 510(k) clearance for a system that monitors CT scans for likely cases intracranial hemorrhage and mass effect, two conditions associated with strokes. The system prioritizes these cases for review from radiologists, letting patients receive a diagnosis faster.
Insightec raises $150M for incisionless surgery
Insightec, a company making an ultrasound device that can be used to treat essential tremor, raised $150 million. The company now has a post-money valuation of $1.3 billion.
Lundbeck to acquire Alder BioPharmaceuticals for nearly $2B
Alder, based in a suburb of Seattle, has a monoclonal antibody that it has investigated as a treatment for migraine and is under FDA review, with the agency expected to decide on its approval in February of next year. Shares of Alder were up 83 percent on the news.
How best to describe precision medicine beyond oncology? ‘It’s complicated.’
While well-developed in cancers, precision medicine's readiness for prime time beyond oncology varies markedly from disease to disease. But reimbursement remains a significant hurdle.
Ovid Therapeutics starts Phase III trial in rare neurological disorder
The trial's primary endpoint will be one for which the drug, OV101, produced encouraging but mixed results in a Phase II study of patients with Angelman syndrome.